NO20005448L - Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert på patologisk celleproliferering - Google Patents

Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert på patologisk celleproliferering

Info

Publication number
NO20005448L
NO20005448L NO20005448A NO20005448A NO20005448L NO 20005448 L NO20005448 L NO 20005448L NO 20005448 A NO20005448 A NO 20005448A NO 20005448 A NO20005448 A NO 20005448A NO 20005448 L NO20005448 L NO 20005448L
Authority
NO
Norway
Prior art keywords
malignant
treatment
cell proliferation
diseases based
pathological cell
Prior art date
Application number
NO20005448A
Other languages
English (en)
Other versions
NO20005448D0 (no
NO317261B1 (no
Inventor
Siavosh Mahboobi
Sabine Kuhr
Herwig Pongratz
Alfred Popp
Harald Hufsky
Frank-D Boehmer
Steffen Teller
Andrea Uecker
Thomas Beckers
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19838506A external-priority patent/DE19838506C2/de
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of NO20005448D0 publication Critical patent/NO20005448D0/no
Publication of NO20005448L publication Critical patent/NO20005448L/no
Publication of NO317261B1 publication Critical patent/NO317261B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
NO20005448A 1998-05-04 2000-10-27 Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert pa patologisk celleproliferering NO317261B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19819835 1998-05-04
DE19838506A DE19838506C2 (de) 1998-05-04 1998-08-25 Indolderivate und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen
PCT/DE1999/001214 WO1999057117A2 (de) 1998-05-04 1999-04-22 Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen

Publications (3)

Publication Number Publication Date
NO20005448D0 NO20005448D0 (no) 2000-10-27
NO20005448L true NO20005448L (no) 2000-10-27
NO317261B1 NO317261B1 (no) 2004-09-27

Family

ID=26045937

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005448A NO317261B1 (no) 1998-05-04 2000-10-27 Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert pa patologisk celleproliferering

Country Status (21)

Country Link
US (2) US6407102B1 (no)
EP (1) EP1109785B1 (no)
JP (1) JP2002514572A (no)
CN (1) CN1151127C (no)
AT (1) ATE230394T1 (no)
AU (1) AU752464B2 (no)
BG (1) BG104996A (no)
BR (1) BR9911017A (no)
CA (1) CA2330756C (no)
CZ (1) CZ20003960A3 (no)
DE (1) DE59903921D1 (no)
DK (1) DK1109785T3 (no)
ES (1) ES2190221T3 (no)
HU (1) HUP0102563A3 (no)
IL (1) IL139056A0 (no)
NO (1) NO317261B1 (no)
NZ (1) NZ507735A (no)
PL (1) PL346840A1 (no)
SK (1) SK16352000A3 (no)
TR (1) TR200003206T2 (no)
WO (1) WO1999057117A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2190221T3 (es) 1998-05-04 2003-07-16 Zentaris Ag Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas.
JP2002527419A (ja) * 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Gsk−3阻害物質としてのピロール−2,5−ジオン類
US6719520B2 (en) 1998-10-08 2004-04-13 Smithkline Beecham Corporation Method and compounds
US6713505B2 (en) * 2000-06-28 2004-03-30 Eli Lilly And Company spla2 inhibitors
EP1310485A4 (en) * 2000-07-28 2005-07-20 Sumitomo Pharma Pyrrole derivatives
TW557298B (en) * 2000-08-14 2003-10-11 Ciba Sc Holding Ag A compound, a photopolymerizible composition, a process for producing coatings and a method for causing a photoinitiator to accumulate at the surface of coatings
US20030032625A1 (en) * 2001-03-29 2003-02-13 Topo Target Aps Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors
DE10143079A1 (de) * 2001-09-03 2003-05-15 Zentaris Ag Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel
US20050267303A1 (en) * 2001-09-04 2005-12-01 Zentaris Ag Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals
EP1479384A1 (en) * 2002-01-30 2004-11-24 Sumitomo Pharmaceuticals Company, Limited Fibrosis inhibitor
US6800655B2 (en) 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2565387A1 (en) * 2004-05-03 2005-11-17 Ilypsa, Inc. Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
MX2008005661A (es) * 2005-11-03 2008-12-15 Ilypsa Inc Inhibidores de fosfolipasa, que incluyen inhibidores de fosfolipasa multivalente, y uso de los mismos, que incluyen como inhibidores de fosfolipasa localizadas en el lumen.
CA2627353A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors
US7666898B2 (en) * 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
WO2007056184A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-a2 inhibitors
CA2627352A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
US20090142832A1 (en) * 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
CN101704828A (zh) * 2009-11-04 2010-05-12 中国科学院昆明植物研究所 山橙素类双吲哚化合物,其药物组合物及其制备方法和用途
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN106317169B (zh) * 2015-06-23 2019-07-02 首都医科大学 双吲哚-二肽衍生物,其合成,抗血栓活性和制备抗血栓剂的应用
WO2018024172A1 (en) * 2016-08-05 2018-02-08 The University Of Hong Kong Platinum complexes and methods of use thereof
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US12523663B2 (en) 2019-06-04 2026-01-13 Inserm (Institut National De La Santé Et De La Rescherche Médicale) Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2026006328A1 (en) * 2024-06-26 2026-01-02 Arizona Board Of Regents On Behalf Of Arizona State University Compositions and methods for mode-selective modulation of transient receptor potential vanilloid-1 (trpv1)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598583A (en) * 1968-08-09 1971-08-10 Itek Corp Indomethylene dye bases and their utilization in photographic processes and compositions
FR2688220A1 (fr) * 1992-03-06 1993-09-10 Adir Nouveaux derives de thiazolidine-2,4-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO1994024117A1 (fr) * 1993-04-22 1994-10-27 Nippon Shinyaku Co., Ltd. Derive de l'acide benzofurancarboxylique et composition pharmaceutique
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0817627T3 (da) * 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
JPH08295688A (ja) * 1995-04-28 1996-11-12 Sharp Corp ビスアゾ化合物、その中間体及びそれらの製造方法、並びにビスアゾ化合物を含有する電子写真感光体
DE19547263C2 (de) * 1995-12-07 1999-04-29 Cardiotec Inc Amidinohydrazone vom Benzo[b]furan abgeleiteter Ketone, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ES2190221T3 (es) 1998-05-04 2003-07-16 Zentaris Ag Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas.

Also Published As

Publication number Publication date
WO1999057117A3 (de) 2001-04-12
TR200003206T2 (tr) 2001-07-23
HUP0102563A2 (hu) 2001-11-28
DK1109785T3 (da) 2003-04-22
US20030008898A1 (en) 2003-01-09
SK16352000A3 (sk) 2002-07-02
HK1038354A1 (en) 2002-03-15
ES2190221T3 (es) 2003-07-16
JP2002514572A (ja) 2002-05-21
NO20005448D0 (no) 2000-10-27
HUP0102563A3 (en) 2003-04-28
CN1310705A (zh) 2001-08-29
CA2330756A1 (en) 1999-11-11
BG104996A (en) 2001-07-31
US6407102B1 (en) 2002-06-18
EP1109785A2 (de) 2001-06-27
NO317261B1 (no) 2004-09-27
PL346840A1 (en) 2002-02-25
NZ507735A (en) 2003-04-29
AU4497599A (en) 1999-11-23
BR9911017A (pt) 2001-02-06
IL139056A0 (en) 2001-11-25
CZ20003960A3 (cs) 2002-04-17
DE59903921D1 (de) 2003-02-06
CA2330756C (en) 2007-10-02
ATE230394T1 (de) 2003-01-15
EP1109785B1 (de) 2003-01-02
WO1999057117A2 (de) 1999-11-11
AU752464B2 (en) 2002-09-19
CN1151127C (zh) 2004-05-26
US6812243B2 (en) 2004-11-02

Similar Documents

Publication Publication Date Title
NO20005448D0 (no) Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert pÕ patologisk celleproliferering
TR200002980T2 (tr) İnhibe edici etkiye sahip ikame edilmiş indolinonlar
YU61402A (sh) Pirol substituisani 2 indolinon protein kinazni inhibitori
TR199900048T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
TR200201144T2 (tr) NFKB aktivitesinin modülasyonu için ikame edilmiş indoller
NZ503828A (en) Aminothiazole inhibitors of cyclin dependent kinases
NO331166B1 (no) Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
ATE292623T1 (de) 2-indolinonderivate als modulatoren der proteinkinase-ativität
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
HUP0101146A2 (hu) Foszfolipáz enzim inhibitor hatású indolszármazékok, valamint a vegyületeket tartalmazó gyógyászati készítmények
BR9709443B1 (pt) n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
CY1106933T1 (el) Ενωσεις πυριμιδινης
MY126235A (en) 3-(4-amidopyrrol-2-ylmethylidene) -2- indolinone derivatives as protein kinase inhibitors.
ATE246184T1 (de) Chinoline und deren therapeutische verwendung
BG104938A (bg) Заместени индолинони, тяхното получаване и тяхното приложение като лекарствени средства
DE60023025D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
BRPI0407841A (pt) inibidores heterocìclicos de quinase
EA200301005A1 (ru) Замещенные в положении 6 индолиноны и их применение в качестве ингибиторов киназ
ATE389655T1 (de) Pyrimidinderivate
BRPI0508881A (pt) derivados de imidazol